# US 2024/0197640 A1 · Systems and methods for exosome delivery of micrornas for cellular reprogramming

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197640 A1
- Document ID: US20240197640A1
- Status: Published application
- Kind: A1
- Application number: 18/474,697
- Filed: 2023-09-26
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Applicants: Duke University
- Inventors: Conrad P. Hodgkinson; Hualing Sun; Victor J. Dzau
- Web page: https://patentgrep.com/patent/US20240197640A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12N 5/069: {Vascular Endothelial cells}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/31: Combination therapy
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure describes, in part, exosomes comprising miRNA for the reprogramming of fibroblasts and methods of using the same.

## Claims

### Claim 1

A loaded exosome comprising an endothelial exosome, and at least one exogenous miR within said endothelial exosome.

### Claim 2 (depends on 1)

The loaded exosome of claim 1, wherein the endothelial exosome is mammalian.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The loaded exosome of claim 1, wherein the at least one exogenous miR is selected from the group consisting of miR1, miR126, miR133, miR138, mir148a-3p, miR206, miR208, miR499-5p and any combination thereof.

### Claim at position 5

5-9. (canceled)

### Claim 10 (depends on 2)

The loaded exosome of claim 2, wherein said mammalian cell exosome is a C166 mammalian exosome.

### Claim at position 7

11-16. (canceled)

### Claim 17

An engineered cell for producing exosomes, comprising a mammalian endothelial cell and a cassette for expression of one or more exogenous miR.

### Claim 18 (depends on 17)

The engineered cell of claim 17, wherein the cell is a C166 cell.

### Claim at position 10

19-20. (canceled)

### Claim 21 (depends on 17)

The engineered cell of claim 17, wherein the at least one exogenous miR is selected from the group consisting of miR1, miR126, miR133, miR138, mir148a-3p, miR206, miR208, miR499-5p and any combinations thereof.

### Claim at position 12

22-26. (canceled)

### Claim 27

A system for cell delivery comprising a loaded exosome and an inhibitor of MDFIC expression.

### Claim 28 (depends on 27)

The system of claim 27, wherein the inhibitor of MDFIC expression comprises a nucleic acid.

### Claim 29 (depends on 28)

The system of claim 28, wherein the nucleic acid is selected from the group consisting of miR, siRNA, and shRNA.

### Claim at position 16

30-31. (canceled)

### Claim 32 (depends on 27)

The system of claim 27, wherein the loaded exosome comprises at least one exogenous miR.

### Claim 33 (depends on 32)

The system of claim 32, wherein the at least one exogenous miR is selected from the group consisting of miR1, miR126, miR133, miR138, mir148a-3p, miR206, miR208, miR499-5p and any combinations thereof.

### Claim at position 19

34-38. (canceled)

### Claim 39 (depends on 1)

A method of reprogramming a cell comprising administering the loaded exosome of claim 1 to a cell.

### Claim 40

A method for manufacturing a loaded exosome comprising:
providing an endothelial cell comprising an inhibitor of MDFIC expression and at least one exogenous miR;
inducing the cell to produce loaded exosomes comprising the at least one exogenous miR; and harvesting the loaded exosome.

### Claim 41 (depends on 40)

The method of claim 40, wherein the endothelial cell is a C166 cell.

### Claim 42 (depends on 27)

A method of reprogramming a cell comprising administering the system of claim 27 to a cell.

### Claim 43 (depends on 40)

The method of claim 40, wherein the at least one exogenous is selected from the group consisting of miR1, miR126, miR133, miR138, mir148a-3p, miR206, miR208, miR499-5p and any combinations thereof

### Claim at position 25

44-48. (canceled)

### Claim 49 (depends on 40)

A loaded exosome manufactured by the method of claim 40 .

### Claim 50 (depends on 1)

A method of treating a cardiac disorder or reducing cardiac fibrosis or improving cardiac function comprising delivering a loaded exosome of claim 1.

### Claim 51 (depends on 50)

The method of claim 50, wherein the loaded exosome is delivered to a cardiac fibroblast-or a cardiac tissue or a myocardium tissue of a mammal.

### Claim 52 (depends on 49)

A method of treating cardiac disorder or reducing cardiac fibrosis or improving cardiac function comprising delivering a loaded exosome of claim 49.

### Claim 53 (depends on 52)

The method of claim 52, wherein the loaded exosome is targeted or delivered to a cardiac fibroblast or a cardiac tissue or a myocardium tissue of a mammal.

### Claim 54 (depends on 51)

The method of claim 51, wherein the mammal is a human.

### Claim 55 (depends on 53)

The method of claim 53, wherein the mammal is a human.

### Claim 56 (depends on 50)

The method of claim 50, wherein the delivery results in the appearance of or increase in the number of cardiomyocytes in the cardiac tissue.

### Claim 57 (depends on 52)

The method of claim 52, wherein the delivery results in the appearance of or increase in the number of cardiomyocytes in the cardiac tissue.

### Claim 58 (depends on 1)

The loaded exosome of claim 1, wherein the endothelial exosome is human endothelial exosome.
